Strategies for managing symptoms of anxiety

References

• American PsychiatricAssociation. Diagnostic and Statistical Manual of Mental Disorders (4Th Edition). American Psychiatric Association, WA, USA (2000).
   Google Scholar
• Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the national comorbidity survey. Arch. Gen. Psych. 51(1), 8–19 (1994).
   PubMed Web of Science ®Google Scholar
• Jenkins R, Lewis G, Bebbington P et al. The national psychiatric morbidity surveys of Great Britain – initial findings from the household survey. Psychol. Med. 27(1–2), 775–789 (1997).
   Google Scholar
• Greenberg PE, Sisitsky T, Kessler RC et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiat 60, 427–435 (1999).
   PubMed Web of Science ®Google Scholar
• Rice DP, Miller LS. The economic burden of mental disorders. Adv. Health Econ. Health. Serv. Res. 14, 37–53 (1993).
   PubMedGoogle Scholar
• Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch. Gen. Psych. 62(6), 593–602 (2005).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Zhao S, Katz SJ et al. Past-year use of outpatient services for psychiatric problems in the National Comorbidity Survey. Am. J. Psych. 156(1), 115–123 (1999).
   PubMed Web of Science ®Google Scholar
• Narrow WE, Regier DA, Rae DS et al. Use of services by persons with mental and addictive disorders: findings from the National Institute of Mental Health Epidemiologic Catchment Area program. Arch. Gen. Psych. 50(2), 95–107 (1993).
   PubMed Web of Science ®Google Scholar
• Collins KA, Westra HA, Dozois DJ, Burns DD. Gaps in accessing treatment for anxiety and depression: challenges for the delivery of care. Clin. Psychol. Rev. 24(5), 583–616 (2004).
   PubMed Web of Science ®Google Scholar
• Hanson L. Quality of life in depression and anxiety. Intern. Rev. Psychiatr. 14, 185–189 (2002).
   Web of Science ®Google Scholar
• Medelowitz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am. J. Psych. 157(5), 669–682 (2000).
   PubMed Web of Science ®Google Scholar
• Sareen J, Cox BJ, Clara I, Asmundson GJG. The relationship between anxiety disorders and physical disorders in the US National Comorbidity Survey. Depression Anxiety 21, 193–202 (2005).
   PubMed Web of Science ®Google Scholar
• LeDoux JE. Emotion circuits in the brain. Annual Rev. Neuroscience 23, 155–184 (2000).
   PubMed Web of Science ®Google Scholar
• Fellous J-M, Armony JL, LeDoux JE. Emotional circuits and computational neuroscience. In: Handbook of Brain Theory and Neural Networks (2nd Edition). MA Arbib (Ed.). MIT Press, USA (2002).
   Google Scholar
• Charney DS. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. Am. J. Psych. 161(2), 195–216 (2004).
   PubMed Web of Science ®Google Scholar
• Pare D, Quirk GJ, LeDoux JE. New vistas on amygdala networks in conditioned fear. J. Neurophys. 92, 1–9 (2004).
   PubMed Web of Science ®Google Scholar
• Sotres-Bayon F, Bush DEA, LeDoux JE. Emotional perseveration: an update on prefrontal–amygdala interactions in fear extinction. Learning Memory 11, 525–535 (2004).
   PubMed Web of Science ®Google Scholar
• Vermetten E, Bremner JD. Circuits and systems in stress, II. Applications to neurobiology and treatment in posttraumatic stress disorder. Depression Anxiety 16(1), 14–38 (2002).
   PubMed Web of Science ®Google Scholar
• Vermetten E, Bremner JD. Circuits and systems in stress, I. Preclinical studies. Depression Anxiety 15(3), 126–147 (2002).
   PubMed Web of Science ®Google Scholar
• Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J. Clin. Psychopharm. 21(3), 311–324 (2001).
   PubMed Web of Science ®Google Scholar
• Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ. Behavioral versus pharmacological treatments of obsessive compulsive disorder. Psychopharm. 136(3), 205–216 (1998).
   PubMed Web of Science ®Google Scholar
• Mitte K. Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. Psychol. Bull. 131, 785–795 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor S. Understanding and Treating Panic Disorder: Cognitive-Behavioral Approaches. Wiley, NY, USA (2000).
   Google Scholar
• Taylor S, Asmundson GJG, Coons MJ. Current directions in the treatment of hypochondriasis. J. Cog. Psychother. 19, 291–310 (2005).
   Google Scholar
• Van Etten M, Taylor S. Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysis. Clin. Psychol. Psychothe. 5, 126–145 (1998).
   Web of Science ®Google Scholar
• Deacon BJ, Abramowitz JS. Cognitive and behavioral treatments for anxiety disorders: a review of meta-analytic findings. J. Clin. Psychol. 60(4), 429–441 (2004).
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Wan GJ, Geissler EC. National trends in the outpatient treatment of anxiety disorders. J. Clin. Psych. 65(9), 1166–1173 (2004).
   Google Scholar
• Fallon BA, Liebowitz MR, Salman E et al. Fluoxetine for hypochondriachal patients without major depression. J. Clin. Psychopharm. 13(6), 438–441 (1993).
   PubMed Web of Science ®Google Scholar
• Fallon BA, Schneier FR, Marshall R et al. The pharmacotherapy of hypochondriasis. Psychopharm. Bull. 32(4), 607–611 (1996).
   PubMedGoogle Scholar
• Mathew SJ, Cooplan JD, Gorman JM. Management of treatment-refractory panic disorder. Psychopharm. Bull. 35, 97–110 (2001).
   PubMedGoogle Scholar
• Schneier FR. Treatment of social phobia with antidepressants. J. Clin. Psych. 62(Suppl. 1), 43–48 (2001).
   Google Scholar
• Sramek JJ, Zarotsky V, Cutler NR. Generalised anxiety disorder: Treatment options. Drugs 62, 1635–1648 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor S, Stein MB. The future of selective serotonin reuptake inhibitors (SSRIs) in psychiatric treatment. Med. Hypoth. (2006) (In press).
   Google Scholar
• Uhlenhuth EH, Balter MB, Ban TA et al. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Treatments in recommendations for the pharmacotherapy of anxiety disorders. Depression Anxiety 9, 107–116 (1999).
   PubMedGoogle Scholar
• Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive–compulsive disorder: double-blind, placebo-controlled study. European NeuroPsychopharm. 15(1), 69–74 (2005).
   Google Scholar
• Westra HA, Stewart SH. Cognitive-behavioral therapy and pharmacotherapy: Complementary or contradictory approaches to the treatment of anxiety? Clin. Psychol. Rev. 18, 307–340 (1998).
   PubMed Web of Science ®Google Scholar
• Foa EB, Franklin ME, Moser J. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol. Psych. 52(10), 987–997 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor S, Asmundson GJG. Treating Health Anxiety: a Cognitive-Behavioral Approach. NY, USA (2004).
   Google Scholar
• American PsychiatricAssociation. Practice guidelines for the treatment of patients with panic disorder. Am. J. Psych. 155(Suppl.), 1–34 (1998).
   Google Scholar
• March JS, Frances A, Kahn DA, Carpenter D. The expert consensus guideline series: treatment of obsessive–compulsive disorder. J. Clin. Psych. 58 (Suppl. 4), (1997).
   Google Scholar
• Foa EB, Davidson JRT, Frances A. The expert consensus guideline series: treatment of posttraumatic stress disorder. J. Clin. Psych. 60(Suppl. 16) (1999).
   Google Scholar
• Garland EJ. Facing the evidence: antidepressant treatment in children and adolescents. Canadian Med. Assoc. J. 170(4), 490–491 (2004).
   Google Scholar
• Taylor S. Cognitive-Behavior Therapy for Posttraumatic Stress Disorder. NY, USA (2006) (In press).
   Google Scholar
• Neziroglu F, Stevens KP, McKay D, Yaryura-Tobias JA. Predictive validity of the overvalued ideas scale: outcome in obsessive-compulsive and body dysmorphic disorders. Behav. Res. Ther. 39(6), 745–756 (2001).
   Google Scholar
• Neziroglu F, Pinto A, Yaryura-Tobias JA, McKay D. Overvalued ideation as a predictor of fluvoxamine response in patients with obsessive-compulsive disorder. Psych. Res. 125(1), 53–60 (2004).
   Google Scholar
• Roy-Byrne P, Berliner L, Russo J, Zatzick D, Pitman RK. Treatment preferences and determinants in victims of sexual and physical assault. J. Nerv. Mental Dis. 191(3), 161–165 (2003).
   PubMed Web of Science ®Google Scholar
• Walker J, Vincent N, Furer P, Cox B, Kjernisted K. Treatment preference in hypochondriasis. J. Behav. Ther. Exper. Psych. 30(4), 251–258 (1999).
   PubMed Web of Science ®Google Scholar
• Lange A, Rietdijk D, Hudcovicova M, van de Ven J, Schrieken,B, Emmelkamp PMG. Interapy: A controlled randomized trial of the standardized treatment of posttraumatic stress through the Internet. J. Consult Clin. Psychol. 71(5), 901–909 (2003).
   PubMed Web of Science ®Google Scholar
• Richards J, Klein B, Carlbring P. Internet-based treatment for panic disorder. Cog. Behav. Ther. 32(3), 125–135 (2003).
   PubMedGoogle Scholar
• Taylor S, Thordarson DS, Spring T et al. Telephone-administered cognitive-behavior therapy for obsessive-compulsive disorder. Cog. Behav. Ther. 32(1), 13–25 (2003).
   PubMedGoogle Scholar
• Durham RC, Fisher PL, Dow MG et al. Cognitive behavior therapy for good and poor prognosis generalized anxiety disorder: a clinical effectiveness study. Clinl. Psychol. Psychother. 11(3), 145–157 (2004).
   Web of Science ®Google Scholar
• Norton PJ, Hope DA. Preliminary evaluation of a broad-spectrum cognitive-behavioral group therapy for anxiety. J. Behav. Ther. Exper. Psych. 36(2), 79–97 (2005).
   PubMed Web of Science ®Google Scholar
• Laposa JM, Janeck AS, Erickson DH, Tallman K. Group CBT for heterogeneous anxiety disorders: preliminary evidence for effectiveness. Proceedings of the 31st annual convention of the British Association for Behavioral and Cognitive Psychotherapies. UK (2003).
   Google Scholar
• Walker DL, Davis M. The role of glutamate receptors within the amygdala in fear learning, fear-potentiated startle, and extinction. Pharmacol. Biochem. Behav. 71, 379–392 (2002).
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Kremer I, Javitt DC et al. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. International J. NeuroPsychopharm. 5(4), 301–307 (2002).
   PubMed Web of Science ®Google Scholar
• Ressler KJ, Rothbaum BO, Tannenbaum L et al. Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to enhance extinction of fear. Arch. Gen. Psych. 61(11), 1136–1144 (2004).
   PubMed Web of Science ®Google Scholar
• Barlow DH. Anxiety and its Disorders (2nd Edition). Guilford Press, NY, USA (2002).
   Google Scholar